Nuvalent Inc. (NUVL), a clinical-stage biopharmaceutical company developing precisely targeted therapies for clinically proven kinase targets in cancer, will be presenting updated data from its ARROS-1 trial and ALKOVE-1 trial in the coming months.
ARROS-1 is a phase I/II clinical trial evaluating the company's lead drug candidate NVL-520 in patients with advanced ROS1-positive non-small cell lung cancer and other solid tumors (ROS1-positive lung cancer develops when the ROS1 gene fuses with an adjacent gene. This type of lung cancer is typically aggressive and has the potential to metastasize to the brain and bones - Source: Lung Cancer Foundation of America).
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com